Anaptysbio Inc (NASDAQ:ANAB) Sellers Rose By 3.2% Their Shorts

May 16, 2018 - By Rhonda Roth

Anaptysbio Inc (NASDAQ:ANAB) had an increase of its short interest by 3.2%. It was published in May by FINRA the 2.60M short interest on ANAB. The up change of 3.2% from 2.52M shares was reported. Anaptysbio Inc (NASDAQ:ANAB) has 264,700 shares average volume. It’ll cost 10 days for ANAB to recover its former position. Anaptysbio Inc float short is 21.69%.

ANAB touched $88.71 during the last trading session after $0.61 change.AnaptysBio, Inc. has volume of 101,764 shares. Since May 16, 2017 ANAB has risen 290.56% and is uptrending. The stock outperformed the S&P500 by 279.01%.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation.The firm is valued at $2.08 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.Currently it has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

A couple more AnaptysBio, Inc. (NASDAQ:ANAB) news were brought out by: Globenewswire.com which released on April 27, 2018 “AnaptysBio To Participate in Upcoming Investor Conferences”, also Streetinsider.com on May 09, 2018 brought out “AnaptysBio (ANAB) PT Lowered to $150 at SunTrust Robinson Humphrey”, the next Streetinsider.com is “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” on May 15, 2018. Nasdaq.com has article titled “AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress”.

AnaptysBio, Inc. (NASDAQ:ANAB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: